8-K: FitLife Brands Q2 2025 Results & Irwin Acquisition

FitLife Brands reports a 5% revenue decline in Q2 2025, alongside reduced net income and EBITDA, while completing the strategic acquisition of Irwin Naturals.

Summary

• Total revenue for the second quarter of 2025 was $16.1 million, a 5% decrease compared to $16.9 million in the second quarter of 2024.
• Net income for Q2 2025 was $1.7 million, down from $2.6 million in Q2 2024, primarily due to $696,000 in merger and acquisition-related expenses associated with the Irwin Naturals transaction.
• Diluted earnings per share were $0.18 for Q2 2025, compared to $0.27 for Q2 2024.
• Adjusted EBITDA decreased by 13% to $3.3 million in Q2 2025 compared to Q2 2024.
• The company completed the acquisition of Irwin Naturals on August 8, 2025, for a total consideration of $42.5 million, funded partly by a new $35.75 million term loan.
• Legacy FitLife business saw revenue increase by 7% to $7.303 million, driven by a 17% increase in online revenue.
• Mimi's Rock (MRC) revenue decreased by 16% to $6.269 million, with the Dr. Tobias brand revenue down 16% and skin care brands down 20%, partly due to a 25% tariff impact.
• MusclePharm revenue decreased by 4% to $2.555 million, though monthly wholesale revenue for MusclePharm in July 2025 was the highest since its acquisition.

Sentiment

Score: 5

Explanation: The quarter's financial results show a decline in key metrics like revenue, net income, and EBITDA, indicating operational challenges, particularly with the MRC segment. However, the strategic acquisition of Irwin Naturals, a significant brand with substantial revenue, presents a strong growth opportunity and potential for future cost synergies, balancing the negative quarterly performance.

Positives

• Legacy FitLife business demonstrated strength with a 7% increase in total revenue to $7.303 million in Q2 2025, including a 17% increase in online revenue.
• The strategic acquisition of Irwin Naturals was completed on August 8, 2025, adding a brand with approximately $60 million in trailing twelve-month revenue (adjusted for Costco distribution loss) and strong distribution.
• Management expects to achieve approximately $1.5 million in annual SG&A cost savings from the Irwin Naturals acquisition, with potential for further efficiencies.
• MusclePharm's monthly wholesale revenue in July 2025 reached its highest point since the brand's acquisition, indicating recent distribution gains.
• The company ended the quarter with a net debt of $4.3 million, equivalent to approximately 0.3x adjusted EBITDA, indicating a relatively low leverage ratio.

Negatives

• Total revenue decreased by 5% to $16.1 million in Q2 2025 compared to $16.9 million in Q2 2024.
• Net income declined significantly to $1.7 million in Q2 2025 from $2.6 million in Q2 2024, primarily due to elevated merger and acquisition-related expenses of $696,000.
• Diluted earnings per share decreased to $0.18 in Q2 2025 from $0.27 in Q2 2024.
• Adjusted EBITDA decreased by 13% to $3.3 million in Q2 2025 compared to Q2 2024.
• Gross margin declined to 42.8% in Q2 2025 from 44.8% in Q2 2024, primarily driven by Mimi's Rock (MRC) performance.
• Mimi's Rock (MRC) revenue decreased by 16% in Q2 2025, with its largest brand, Dr. Tobias, declining 16% and skin care brands declining 20%.
• The decline in Dr. Tobias brand revenue is attributed to a drop in traffic to product listing pages.
• Skin care brands within MRC were negatively impacted by a 25% tariff applied to the full product cost on the majority of their revenue.

Risks

• Ability to continue to grow revenue.
• Ability to continue to achieve positive cash flow given existing and anticipated operating and other costs.
• Ability to service its debt.
• Decline in traffic to product listing pages for the Dr. Tobias brand, which is a primary concern for management.
• Impact of tariffs (specifically 25% tariff on skin care brands) on gross margins.
• Wholesale revenue for MusclePharm can be 'lumpy,' meaning quarter-to-quarter figures may not accurately reflect progress.

Future Outlook

Management expects improved gross margins for Irwin Naturals over time by increasing online sales and optimizing the supply chain. They also anticipate identifying further cost-savings opportunities within Irwin's operations beyond the initial $1.5 million annual SG&A reduction. For the Dr. Tobias brand, initiatives are underway to increase session counts, including targeted advertising spend, SEO optimization, and driving external traffic, with expectations for more favorable year-over-year comparisons beginning later in the year if session counts remain stable.

Management Comments

• The second quarter of 2025 was strong for our Legacy FitLife business, but somewhat challenged for MRC.
• Among our existing brands, the performance of the Dr. Tobias brand is our primary concern, primarily due to reduced session counts on Amazon.
• Once customers get to the brands product pages, they are converting at the same or higher percentages.
• We are focused on a number of initiatives to increase session counts, including targeted increases in advertising spend, optimizing SEO for our listings, and driving external traffic to our Amazon product pages.
• As long as session counts continue to remain stable, the year-over-year comparison should be more favorable beginning later this year.
• The efforts of our sales team continue to bear fruit. We continue to gain new distribution for a number of products, including the RTDs.
• Wholesale revenue for this brand [MusclePharm] is somewhat lumpy, so quarter-to-quarter wholesale revenue may not accurately reflect our progress.
• Monthly wholesale revenue for MusclePharm in July was the highest it has ever been since we bought the brand.
• We are very excited about Irwin Naturals.
• We expect to generate improved gross margins over time as we increase the percentage of revenue generated from online sales and as we focus on making our supply chain more efficient.
• We expect annual SG&A to be approximately $1.5 million lower based on the number of employees rehired by FitLife as part of the transaction. And we expect to identify further cost-savings opportunities as we become more familiar with Irwins operations.
• Irwin has an incredible brand with strong distribution. And we are equally excited about the Irwin team and are delighted to welcome them to the FitLife family.

Industry Context

The nutritional supplements and wellness products industry continues to see shifts between online and wholesale channels. The acquisition of Irwin Naturals by FitLife Brands reflects ongoing consolidation and strategic moves within the sector, as companies seek to expand brand portfolios and market reach, particularly through distressed asset purchases (Section 363 bankruptcy). Challenges like declining online traffic for specific brands (e.g., Dr. Tobias on Amazon) and the impact of tariffs highlight the dynamic and sometimes volatile nature of e-commerce and international trade in this industry. Companies are focusing on optimizing digital marketing (SEO, advertising spend) and supply chain efficiencies to counter these pressures.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks.

Stakeholder Impact

• Shareholders: Experienced a decline in earnings per share, but the strategic acquisition of Irwin Naturals could offer long-term growth potential and diversification.
• Employees: The Irwin team is welcomed into the FitLife family, indicating potential integration and new opportunities for employees from both entities.
• Customers: New MusclePharm Pro Series products are being launched, and efforts are underway to improve product listing visibility for Dr. Tobias, potentially enhancing customer experience and product availability.
• Creditors: A new term loan and revolving line of credit from First Citizens Bank were secured to fund the Irwin acquisition, indicating new debt obligations.

Next Steps

• Hold an investor conference call on Thursday, August 14, 2025, at 4:30 pm ET.
• Update investors on Irwin Naturals' progress during the third quarter earnings call.
• Implement initiatives to increase session counts for the Dr. Tobias brand, including targeted advertising spend, SEO optimization, and driving external traffic.
• Identify further cost-savings opportunities within Irwin Naturals' operations.
• Increase the percentage of revenue generated from online sales for Irwin Naturals.
• Focus on making Irwin Naturals' supply chain more efficient.

Key Dates

Recommendation

While the second quarter financial results show a decline in revenue, net income, and EBITDA, reflecting operational headwinds in certain segments like Mimi's Rock, the strategic acquisition of Irwin Naturals is a significant long-term growth driver. The acquisition adds a substantial revenue base and brand strength, with anticipated cost synergies. The mixed performance, with core business challenges offset by a transformative acquisition, suggests a 'hold' recommendation as investors await further integration progress and the realization of synergies from the Irwin Naturals deal. The low net debt position provides some financial flexibility.

Keywords

Nutritional supplements, wellness products, FitLife Brands, FTLF, Q2 2025 earnings, financial results, Irwin Naturals, acquisition, MusclePharm, Dr. Tobias, Mimi's Rock, EBITDA, revenue, net income, corporate acquisition, consumer health